Bryan Garnier - 4D Pharma (DDDD) 4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D

Report

Bryan Garnier

Olga Smolentseva

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D

Blautix showed encouraging activity on bowel habit in IBS patients
Blautix could be well positioned in IBS-M
Anticipating the full data to be released by the end of 2020

07/10/2020 3 EN

Underlying

4D Pharma

4D Pharma is engaged in research and development of pharmaceutical products in live biotherapeutic areas.

See profile

GB00BJL5BR07 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

Coverage dropped

October 11, 2022 October 11, 2022 1 EN

UOB

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

The yoy growth of total RSV was faster in Aug 22 (5.4%) than in Jul 22 (2.7%) on the low base in Aug 21. Despite near-term consumption being largely decided by the pandemic situation, we expect better consumption in 2H22 than in 1H22. We suggest watching four key areas in the consumer space: a) further increase in concentration (eg Jonjee), b) low penetration (eg duty-free), c) easing cost pressure (eg beer), and d) strong pricing power (eg Moutai). Maintain OVERWEIGHT on China’s consumer sector.

September 19, 2022 September 19, 2022 1 EN

BusinessWire

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion. The ongoing study is being conducted in...

March 23, 2022 March 23, 2022 1 EN

L'Oréal reports encouraging Q1 2024 sales figures

L'Oréal's Q1 sales were above market expectations. Excluding a technical one-off positive impact, sales grew 8.1% lfl over the quarter (consensus: +6.4%) thanks to strong performances in the mass market and Derma Beauty divisions. L'Oréal continued to outperform a still dynamic beauty market (+6%).

21h / 2m 21h / 2m 1 EN

Clement Genelot

Clement Genelot

Food Delivery: diverging growth/FCF profiles

Post TKWY and ROO's Q1 figures and ahead of DHER's publication, we note an improving growth trend in Q1. This growth will nevertheless have to rebalance towards orders as out-of-home food is also set to face disinflation this year. The ability to recreate HSD% growth will be the name of the 2024-25

21h / 14m 21h / 14m 1 EN

Cedric Rossi

Cedric Rossi

EssilorLux: in-line Q1 sales performance and good vibes ahead of Q2

Yesterday evening, EssilorLux unveiled Q1 sales up 5.5% FX-n to EUR6.34bn, fairly in line with CSSe (EUR6.38bn) despite a tough comp base and unfavourable calendar effect. We see room for accelerating trends given increased tailwinds from: 1/ pricing in frames (BGe: MSD price hike), 2/ the ramp-up

21h / 14m 21h / 14m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D

Coverage dropped

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

L'Oréal reports encouraging Q1 2024 sales figures

Food Delivery: diverging growth/FCF profiles

EssilorLux: in-line Q1 sales performance and good vibes ahead of Q2

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe